

## 論文 (2013 年以降)

1. Kario K, Ando S, Kido H, Nariyama J, Takiuchi S, Yagi T, Shimizu T, Eguchi K, Ohno M, Kinoshita O, Yamada T, APPENDIX Nunohiro T. The effects of the L/N-type calcium channel blocker (cilnidipine) on sympathetic hyperactive morning hypertension: results from ACHIEVE-ONE. *Journal of Clinical Hypertension* 2013 Feb; 15(2): 133-42.
2. White WB, Cannon CP, Heller SR; EXAMINE Investigators, Collaborators Nunohiro T. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. *N Engl J Med.* 2013 Oct 3; 369(14): 1327-35.
3. Hokusai-VTE Investigators, Büller HR, Décousus H, Wells P, Collaborators Nunohiro T. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. *N Engl J Med.* 2013 Oct 10; 369(15): 1406-15.
4. Pieske B, Butler J, Gheorghiade M; SOCRATES Investigators and Coordinators, Collaborators Nunohiro T. Rationale and design of the SOLuble guanylate Cyclase stimulator in heArT failure Studies (SOCRATES). *Eur J Heart Fail.* 2014 Sep; 16(9): 1026-38.
5. Bentley-Lewis R, Aguilar D, McMurray JJ, Ping L, Probstfield JL, Solomon SD, Tardif JC, Wu Y, Pfeffer MA; ELIXA Investigators, Collaborators Nunohiro T. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. *Am Heart J.* 2015 May; 169(5): 631-638.e7.
6. Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, Ponikowski P, Shah SJ, Solomon SD, Kraigher-Krainer E, Samano ET, Müller K, Roessig L, Pieske B; SOCRATES-REDUCED Investigators and Coordinators, Collaborators Nakashima H, Nunohiro T, Furudono S. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. *JAMA.* 2015 Dec 1; 314(21): 2251-62.
7. Pfeffer MA, Claggett B, Tardif JC; ELIXA Investigators, Collaborators Nunohiro T. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. *N Engl J Med.* 2015 Dec 3; 373(23): 2247-57.
8. Sabatine MS, Giugliano RP, Pedersen TR; FOURIER Steering Committee and Investigators, Collaborators Nunohiro T. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. *N Engl J Med.* 2017 May 4; 376(18): 1713-1722.
9. Zannad F, Anker SD, Byra WM; COMMANDER HF Investigators, Collaborators Nunohiro T. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary

Disease. *N Engl J Med.* 2018 Oct 4; 379(14): 1332-1342.

10. McMurray JJV, Solomon SD, Inzucchi SE, Appendix Nunohiro T. Dapagliflozin in patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med.* 2019 Nov 21; 381: 1995-2008.
11. Armstrong PW, Pieske B, O'Connor CM; VICTORIA Study Group. Collaborators Nunohiro T. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med.* 2020 May 14;382(20):1883-1893.
12. Okumura K, Akao M, Yamashita T; ELDERCARE- AF Committees and Investigators. Collaborators Nunohiro T. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. *N Engl J Med.* 2020 Oct 29;383(18):1735-1745
13. Docherty KF, Jhund PS, McMurray JJV; DAPA-HF Investigators and Committees. Collaborators Nunohiro T. Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. *Diabetes Care.* 2020 Nov;43(11):2878-2881.
14. Lam CSP, Giczewska A, Sliwa K; VICTORIA Study Group. Collaborators Nunohiro T. Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial. VICTORIA Study Group. Collaborators Nunohiro T. *JAMA Cardiol.* 2021 Jun 1;6(6):706-712.
15. Docherty KF, Jhund PS, McMurray JJV; DAPA-HF Investigators and Committees. Collaborators Nunohiro T . Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. *JAMA Cardiol.* 2021 Jul 28. Online ahead of print
16. Liver stiffness assessed by Fibrosis-4 index predicts heart failure in AMI patients  
T Nunohiro, K Furukawa, S Kuwasaki, S Kusumoto, S Furudono, M Takeno  
*European Heart Journal*, Volume 43, Issue Supplement 1, February 2022, ehab849.07804